Thrasos Therapeutics
logo BDC

Thrasos Therapeutics

Thrasos is a private, clinical‑stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company has two major programs; its lead program targets acute kidney injury (AKI) while the second program addresses diabetic nephropathy, a leading cause of chronic kidney disease (CKD).

Investment year:  2015
Industry sector:  Drugs
Region:  Quebec
Follow Thrasos Therapeutics

Recent news

Thrasos Announces Promising Results for Phase 2 THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI)

Learn More